At MediMabBio, our focus is to engineer new protein therapeutics that modulate T cells – the master regulator of immune response. T cell dysfunctions are often the root cause of many diseases including cancer, where tumors develop sophisticated evasive mechanisms to avoid anti-tumor immune responses, and autoimmune diseases, where malfunctioning T cells contribute to hyperactivation of immune responses damaging normal, healthy tissues.
To overcome the limitations of conventional immunotherapeutics, our approach is centered on rational design: a dynamic process that harnesses the power of computational modeling, structural biology insights, and cutting-edge molecular engineering. This involves going beyond the conventional hit-based discovery methods, and we employ a rigorous workflow to predict and optimize the characteristics of our drug candidates. Our approach allows us to engineer protein therapeutics with unparalleled precision, ensuring enhanced specificity, potency, and safety profiles.
